Skip to content
2000
Volume 18, Issue 2
  • ISSN: 1872-2105
  • E-ISSN: 2212-4020

Abstract

Tuberculosis (TB) is considered a significant health problem caused by . It is one of the second-deadly infectious diseases right after AIDS. Several factors such as poor patient compliance, high dose intake, low drug bioavailability and prolonged treatment of disease are responsible for the prevalence of multi-drug resistance tuberculosis and extensively drug-resistant tuberculosis cases. Therefore, developing such drug-resistant bacterial strains has created a robust and efficient system that can improve the therapeutic effectiveness of anti-tubercular drugs. This review manuscript highlights the therapeutic outcomes of a nanotechnology-based drug delivery system in treating TB. Various novel nanoformulations for anti-mycobacterial drugs have been explored. Such novel approaches would have shown several advantages such as sustained/controlled drug release, reduced dose frequency, and resolved poor patient compliance over many free anti-tubercular drugs. This framework will provide valuable information on various nanoparticle-based technology employed in treating TB infectious disease. Patent data were searched in google patent and nanoformulations outcomes for TB management improves health of patients.

Loading

Article metrics loading...

/content/journals/nanotec/10.2174/1872210516666220523122724
2024-06-01
2025-09-04
Loading full text...

Full text loading...

/content/journals/nanotec/10.2174/1872210516666220523122724
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test